| Type | Features | Organism | Treatment |
|---|---|---|---|
| Non-purulent cellulitis | Diffuse erythema, warmth, tenderness. No abscess, no pus, no drainage. Clear borders. | Beta-hemolytic strep (Group A strep) is the most common cause. NOT usually MRSA. | Cefazolin (Ancef) 2g IV q8h (inpatient) or cephalexin 500 mg QID (outpatient). 5โ6 days is sufficient IDSA, 2014. No MRSA coverage needed. |
| Purulent cellulitis / abscess | Fluctuant, drainable collection. Pus expressed. Central pustule or wound. | S. aureus (MSSA or MRSA) -especially CA-MRSA (USA300). | I&D is the primary treatment (antibiotics alone are less effective). Talan et al. (NEJM), 2016 Antibiotics: TMP-SMX (Bactrim) DS BID or doxycycline (Vibramycin) 100 mg BID ร 5โ7 days. IV: vancomycin if severe. |
| Necrotizing fasciitis SURGICAL EMERGENCY | Pain out of proportion, crepitus, rapid spread, bullae, skin necrosis, hemodynamic instability. LRINEC score โฅ 6 โ high suspicion. | Type I: polymicrobial. Type II: Group A strep (monomicrobial). | Emergent surgical debridement (do NOT wait for imaging). Vanc + pip-tazo + clindamycin (clindamycin inhibits toxin production). ICU. |
| Severity | Treatment | Duration | Key Points |
|---|---|---|---|
| Mild (outpatient) Non-purulent, no systemic signs | Cephalexin (Keflex) 500 mg PO QID | 5โ7 days Hepburn et al., 2004 | Covers Group A strep. No MRSA coverage needed. Elevate limb, mark borders, follow-up in 48h. |
| Moderate (inpatient) Systemic signs, rapid spread, failed PO | Cefazolin (Ancef) 2g IV q8h | Transition to PO at 48โ72h | Admit if: fever, tachycardia, WBC > 15K, rapidly spreading, immunocompromised, facial/periorbital/hand cellulitis. |
| Purulent / Abscess Fluctuance, drainable collection | I&D primary + TMP-SMX DS PO BID or doxycycline 100 mg PO BID | 5โ7 days | I&D is the definitive treatment, antibiotics alone are inferior. Daum et al. (NEJM), 2017 Send wound culture. Pack wound, recheck in 48h. |
| Severe / Necrotizing Fasciitis SURGICAL EMERGENCY | Vancomycin + pip-tazo 4.5g IV q6h + clindamycin 900 mg IV q8h | Until surgical debridement + clinical improvement | Pain out of proportion, crepitus, bullae, rapid spread โ call surgery immediately. Clindamycin inhibits toxin production. Do NOT delay for imaging. |
| Parameter | Frequency | Target / Action |
|---|---|---|
| Demarcation line progression | Mark and remeasure daily (at least q12h if concern for rapid spread) | Erythema receding past marked borders = responding. Spreading beyond marks at 48h โ broaden antibiotics, image for abscess, or consider necrotizing fasciitis. |
| WBC | Daily while on IV antibiotics | Trending down = responding. Rising or persistently elevated โ consider treatment failure, abscess, deeper infection, or wrong diagnosis. |
| Fever curve | q4h (Tmax documented daily) | Afebrile ร 24h is one criterion for IV โ PO transition. Persistent fever > 48h on appropriate antibiotics โ re-evaluate diagnosis and coverage. |
| IV โ PO transition criteria | Assess daily starting at 48h | Transition to oral when: afebrile ร 24h, WBC trending down, erythema receding past marked borders, tolerating PO, systemically well. Usually at 48โ72h. |
| Wound check (if I&D performed) | Daily until packing removed | Wound packing removed or changed at 48h. Assess for re-accumulation, ongoing drainage, surrounding cellulitis. Consider wound culture if not improving. |
| Scenario | Drug (Brand) | Dose | Notes |
|---|---|---|---|
| Non-purulent cellulitis (outpatient) 1ST LINE | Cephalexin (Keflex) | 500 mg PO QID ร 5โ7 days | Covers beta-hemolytic strep (Group A). No MRSA coverage needed. Shorter courses (5 days) are effective IDSA, 2014. |
| Non-purulent cellulitis (inpatient) 1ST LINE | Cefazolin (Ancef) | 2g IV q8h | Transition to cephalexin PO when afebrile ร 24h, WBC trending down, erythema receding past marked borders. |
| Purulent / abscess (MRSA coverage) | TMP-SMX (Bactrim) DS or Doxycycline (Vibramycin) | TMP-SMX DS 1 tab PO BID ร 5โ7 days Doxycycline 100 mg PO BID ร 5โ7 days | I&D is the primary treatment for abscess -antibiotics are adjunctive. Both cover CA-MRSA. TMP-SMX: avoid in pregnancy, check Kโบ (can cause hyperkalemia). Doxycycline: photosensitivity, avoid in pregnancy. |
| Severe / necrotizing fasciitis EMERGENT | Vancomycin + piperacillin-tazobactam (Zosyn) + clindamycin (Cleocin) | Vanc: 15โ20 mg/kg IV q8โ12h (target AUC/MIC 400โ600) Pip-tazo: 4.5g IV q6h Clindamycin: 900 mg IV q8h | Clindamycin inhibits toxin production (ribosomal suppression) -critical for toxin-mediated disease (GAS, S. aureus). Broad coverage for polymicrobial (Type I) and monomicrobial (Type II) nec fasc. Emergent surgical debridement is definitive treatment. |